| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Camp4 Therapeutics Corporation
13D/A
CAMP · 13463J101
|
6.3% |
8/19/2026
Event 8/13/2026
|
||||
| Polaris Management Co. VII, L.L.C. | 4.8% | |||||
| Polaris Partners VII, L.P. | 4.5% | |||||
| Polaris Entrepreneurs' Fund VII, L.P. | 0.3% | |||||
| Polaris Partners GP X, L.L.C. | 1.4% | |||||
| Polaris Partners X, L.P. | 1.4% | |||||
| Amir Nashat | 6.3% | |||||
| Brian Chee | 1.4% | |||||
| Amy Schulman | 1.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.